Paolo Pozzilli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/43381/publications.pdf

Version: 2024-02-01

214 papers	8,506 citations	47 h-index	83 g-index
		47006	56724
238 all docs	238 docs citations	238 times ranked	9654 citing authors

#	Article	IF	Citations
1	The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Human Molecular Genetics, 1996, 5, 1075-1080.	2.9	686
2	Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. New England Journal of Medicine, 2017, 377, 2337-2348.	27.0	322
3	Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet, The, 2013, 381, 1905-1915.	13.7	301
4	Autoimmune Diabetes Not Requiring Insulin at Diagnosis (Latent Autoimmune Diabetes of the Adult): Definition, characterization, and potential prevention. Diabetes Care, 2001, 24, 1460-1467.	8.6	257
5	Adult-Onset Autoimmune Diabetes in Europe Is Prevalent With a Broad Clinical Phenotype. Diabetes Care, 2013, 36, 908-913.	8.6	253
6	Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of Î²-Cell Function in Therapeutic Trials in Type 1 Diabetes. Diabetes Care, 2008, 31, 1966-1971.	8.6	250
7	Modulation of gut microbiota dysbioses in type 2 diabetic patients by macrobiotic Ma-Pi 2 diet. British Journal of Nutrition, 2016, 116, 80-93.	2.3	181
8	Low Levels of 25-hydroxyvitamin D3and 1,25-dihydroxyvitamin D3in Patients with Newly Diagnosed Type 1 Diabetes. Hormone and Metabolic Research, 2005, 37, 680-683.	1.5	176
9	Commentary: Testosterone, a key hormone in the context of COVID-19 pandemic. Metabolism: Clinical and Experimental, 2020, 108, 154252.	3.4	143
10	BMI and BMD: The Potential Interplay between Obesity and Bone Fragility. International Journal of Environmental Research and Public Health, 2016, 13, 544.	2.6	137
11	Low-Dose Otelixizumab Anti-CD3 Monoclonal Antibody DEFEND-1 Study: Results of the Randomized Phase III Study in Recent-Onset Human Type 1 Diabetes. Diabetes Care, 2014, 37, 2746-2754.	8.6	133
12	Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel. Diabetes, 2020, 69, 2037-2047.	0.6	129
13	Type 1 Diabetes and Latent Autoimmune Diabetes in Adults: One End of the Rainbow. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1654-1659.	3.6	121
14	Diabetes classification: grey zones, sound and smoke: Action LADA 1. Diabetes/Metabolism Research and Reviews, 2008, 24, 511-519.	4.0	115
15	Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. Diabetes/Metabolism Research and Reviews, 2016, 32, 21-39.	4.0	115
16	Glycemic variability in the development of cardiovascular complications in diabetes. Diabetes/Metabolism Research and Reviews, 2018, 34, e3047.	4.0	109
17	Metabolic Syndrome and Autoimmune Diabetes: Action LADA 3. Diabetes Care, 2009, 32, 160-164.	8.6	104
18	The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes/Metabolism Research and Reviews, 2010, 26, 239-244.	4.0	104

#	Article	IF	Citations
19	Vitamin K and osteoporosis: Myth or reality?. Metabolism: Clinical and Experimental, 2017, 70, 57-71.	3.4	103
20	Recommendations for management of diabetes during Ramadan: update 2015. BMJ Open Diabetes Research and Care, 2015, 3, e000108.	2.8	101
21	Placeboâ€controlled, randomized trial of the addition of onceâ€weekly glucagonâ€like peptideâ€1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (<scp>AWARD</scp>â€9). Diabetes, Obesity and Metabolism, 2017, 19, 1024-1031.	4.4	98
22	<scp>DPP4</scp> inhibition: Preventing <scp>SARSâ€CoV</scp>â€2 infection and/or progression of <scp>COVID</scp>â€19?. Diabetes/Metabolism Research and Reviews, 2020, 36, e3330.	4.0	95
23	Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II). Cardiovascular Diabetology, 2020, 19, 164.	6.8	90
24	Intervertebral disc degeneration: A focus on obesity and type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2020, 36, e3224.	4.0	82
25	Ageâ€dependent decline of Î²â€cell function in type 1 diabetes after diagnosis: a multiâ€centre longitudinal study. Diabetes, Obesity and Metabolism, 2014, 16, 262-267.	4.4	79
26	Computed Tomography Highlights Increased Visceral Adiposity Associated With Critical Illness in COVID-19. Diabetes Care, 2020, 43, e129-e130.	8.6	79
27	A new expression of diabetes: double diabetes. Trends in Endocrinology and Metabolism, 2007, 18, 52-57.	7.1	77
28	Sclerostin Regulation, Microarchitecture, and Advanced Glycation Endâ€Products in the Bone of Elderly Women With Type 2 Diabetes. Journal of Bone and Mineral Research, 2020, 35, 2415-2422.	2.8	76
29	Erectile dysfunction and diabetes: A melting pot of circumstances and treatments. Diabetes/Metabolism Research and Reviews, 2022, 38, e3494.	4.0	74
30	Insulin secretion in patients with latent autoimmune diabetes (LADA): half way between type 1 and type 2 diabetes: action LADA 9. BMC Endocrine Disorders, 2015, 15, 1.	2.2	73
31	Epigenetics in autoimmune diseases with focus on type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2013, 29, 8-18.	4.0	72
32	The Alliance of Mesenchymal Stem Cells, Bone, and Diabetes. International Journal of Endocrinology, 2014, 2014, 1-26.	1.5	72
33	Combination immunotherapies for type 1 diabetes mellitus. Nature Reviews Endocrinology, 2015, 11, 289-297.	9.6	72
34	Latent Autoimmune Diabetes in Adults in the United Arab Emirates: Clinical Features and Factors Related to Insulin-Requirement. PLoS ONE, 2015, 10, e0131837.	2.5	68
35	Latent Autoimmune Diabetes in Adults: A Review on Clinical Implications and Management. Diabetes and Metabolism Journal, 2018, 42, 451.	4.7	67
36	Effects of COVID-19 Lockdown on Glucose Control: Continuous Glucose Monitoring Data From People With Diabetes on Intensive Insulin Therapy. Diabetes Care, 2020, 43, e86-e87.	8.6	67

#	Article	IF	Citations
37	Obesity, Autoimmunity, and Double Diabetes in Youth. Diabetes Care, 2011, 34, S166-S170.	8.6	65
38	Autoantibodies to Posttranslationally Modified Type II Collagen as Potential Biomarkers for Rheumatoid Arthritis. Arthritis and Rheumatism, 2013, 65, 1702-1712.	6.7	59
39	BCG vaccine in insulin-dependent diabetes mellitus. Lancet, The, 1997, 349, 1520-1521.	13.7	57
40	The Protein Tyrosine Phosphatase Nonreceptor 22 (PTPN22) Is Associated With High GAD Antibody Titer in Latent Autoimmune Diabetes in Adults. Diabetes Care, 2008, 31, 534-538.	8.6	56
41	Saxagliptin improves glycaemic control and Câ€peptide secretion in latent autoimmune diabetes in adults (LADA). Diabetes/Metabolism Research and Reviews, 2016, 32, 289-296.	4.0	54
42	Risk factors for fragility fractures in type 1 diabetes. Bone, 2019, 125, 194-199.	2.9	52
43	Antibodies to post-translationally modified insulin in type 1 diabetes. Diabetologia, 2015, 58, 2851-2860.	6.3	51
44	Latent Autoimmune Diabetes in Adults: Current Status and New Horizons. Endocrinology and Metabolism, 2018, 33, 147.	3.0	51
45	Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study). European Journal of Endocrinology, 1997, 137, 234-239.	3.7	49
46	Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2002, 18, 114-117.	4.0	49
47	Latent autoimmune diabetes in adults is perched between type 1 and type 2: evidence from adults in one region of Spain. Diabetes/Metabolism Research and Reviews, 2013, 29, 446-451.	4.0	49
48	Laser Ablation Versus Radiofrequency Ablation for Benign Non-Functioning Thyroid Nodules: Six-Month Results of a Randomized, Parallel, Open-Label, Trial (LARA Trial). Thyroid, 2020, 30, 847-856.	4.5	49
49	Type I Diabetes Masquerading as Type II Diabetes: Possible implications for prevention and treatment. Diabetes Care, 1994, 17, 1214-1219.	8.6	47
50	Double or hybrid diabetes associated with an increase in type 1 and type 2 diabetes in children and youths. Pediatric Diabetes, 2007, 8, 88-95.	2.9	47
51	Association of TCF7L2 gene variants with low GAD autoantibody titre in LADA subjects (NIRAD) Tj ETQq1 1 0.784314 rgBT /Over	2.3	47
52	Clinical phenotype and Î²-cell autoimmunity in Italian patients with adult-onset diabetes. European Journal of Endocrinology, 2006, 154, 441-447.	3.7	46
53	The SAGE study: Global observational analysis of glycaemic control, hypoglycaemia and diabetes management in T1DM. Diabetes/Metabolism Research and Reviews, 2021, 37, e3430.	4.0	44
54	Latent autoimmune diabetes in the adults (LADA) in Asia: from pathogenesis and epidemiology to therapy. Diabetes/Metabolism Research and Reviews, 2012, 28, 40-46.	4.0	43

#	Article	IF	Citations
55	Beneficial Effects of Physical Activity in Diabetic Patients. Journal of Functional Morphology and Kinesiology, 2020, 5, 70.	2.4	43
56	Double Diabetes: A Mixture of Type 1 and Type 2 Diabetes in Youth. Endocrine Development, 2009, 14, 151-166.	1.3	42
57	Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A postâ€hoc analysis of the AWARDâ€2, â€4 and â€5 Trials. Diabetes, Obesity and Metabolism, 2018, 20, 1490-1498.	4.4	40
58	The DPT-1 trial: a negative result with lessons for future type 1 diabetes prevention. Diabetes/Metabolism Research and Reviews, 2002, 18, 257-259.	4.0	39
59	In vivo corneal confocal microscopy as a novel nonâ€invasive tool to investigate cardiac autonomic neuropathy in Type 1 diabetes. Diabetic Medicine, 2015, 32, 262-266.	2.3	39
60	Diabetes and disordered bone metabolism (diabetic osteodystrophy): time for recognition. Osteoporosis International, 2016, 27, 1931-1951.	3.1	37
61	Antibodies to post-translationally modified insulin as a novel biomarker for prediction of type 1 diabetes in children. Diabetologia, 2017, 60, 1467-1474.	6.3	37
62	Clinical, Biochemical, and Radiological Profile of Normocalcemic Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2609-e2616.	3.6	37
63	The effect of the macrobiotic Ma-Pi 2 diet vs. the recommended diet in the management of type 2 diabetes: the randomized controlled MADIAB trial. Nutrition and Metabolism, 2014, 11, 39.	3.0	35
64	Detection of Insulitis by Pancreatic Scintigraphy With 99mTc-Labeled IL-2 and MRI in Patients With LADA (Action LADA 10). Diabetes Care, 2015, 38, 652-658.	8.6	35
65	Glucose evaluation trial for remission (GETREM) in type 1 diabetes: a European multicentre study. Diabetes Research and Clinical Practice, 2005, 68, 258-264.	2.8	34
66	HLA-dependent autoantibodies against post-translationally modified collagen type II in type 1 diabetes mellitus. Diabetologia, 2013, 56, 563-572.	6.3	34
67	Prevention of type 2 diabetes mellitus: is it feasible?. Diabetes/Metabolism Research and Reviews, 2014, 30, 4-12.	4.0	34
68	Serum Sclerostin and Bone Turnover in Latent Autoimmune Diabetes in Adults. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1921-1928.	3.6	34
69	Global status of diabetes prevention and prospects for action: A consensus statement. Diabetes/Metabolism Research and Reviews, 2018, 34, e3021.	4.0	34
70	Câ€peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective. Diabetes, Obesity and Metabolism, 2022, 24, 1912-1926.	4.4	34
71	Erectile dysfunction and its management in patients with diabetes mellitus. Reviews in Endocrine and Metabolic Disorders, 2015, 16, 213-231.	5.7	32
72	Clopidogrel Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients Treated With Percutaneous Coronary Intervention. Circulation, 2016, 134, 835-837.	1.6	32

#	Article	IF	Citations
73	Clinical features of patients with type 2 diabetes with and without Covid-19: A case control study (CoViDiab I). Diabetes Research and Clinical Practice, 2020, 169, 108454.	2.8	32
74	Inverse Relationship Between Organ-Specific Autoantibodies and Systemic Immune Mediators in Type 1 Diabetes and Type 2 Diabetes: Action LADA 11. Diabetes Care, 2016, 39, 1932-1939.	8.6	31
75	Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 2023, 21, 1523-1532.e1.	4.4	31
76	Raman Spectroscopy Applied to Parathyroid Tissues: A New Diagnostic Tool to Discriminate Normal Tissue from Adenoma. Analytical Chemistry, 2018, 90, 847-854.	6.5	30
77	Blood ketone bodies in patients with recent-onset type 1 diabetes (a multicenter study). Pediatric Diabetes, 2006, 7, 223-228.	2.9	29
78	Incremental role of glycaemic variability over HbA1c in identifying type 2 diabetic patients with high platelet reactivity undergoing percutaneous coronary intervention. Cardiovascular Diabetology, 2019, 18, 147.	6.8	29
79	Impact of obesity on the increasing incidence of type 1 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 1009-1013.	4.4	28
80	Review of clinical trials: update on oral insulin spray formulation. Diabetes, Obesity and Metabolism, 2010, 12, 91-96.	4.4	27
81	One size does not fit all glycemic targets for type 2 diabetes. Journal of Diabetes Investigation, 2014, 5, 134-141.	2.4	27
82	Longâ€term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85). Diabetes, Obesity and Metabolism, 2019, 21, 2115-2122.	4.4	27
83	Osteoarthritis and type 2 diabetes: From pathogenetic factors to therapeutic intervention. Diabetes/Metabolism Research and Reviews, 2020, 36, e3254.	4.0	26
84	Body weight and beauty: the changing face of the ideal female body weight. Obesity Reviews, 2011, 12, 62-65.	6.5	25
85	Laser Ablation Versus Radiofrequency Ablation for Thyroid Nodules: 12-Month Results of a Randomized Trial (LARA II Study). Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1692-1701.	3.6	25
86	The potential role of nicotinamide in the secondary prevention of IDDM. Diabetes/metabolism Reviews, 1993, 9, 219-230.	0.3	24
87	A 2-Year Pilot Trial of Continuous Subcutaneous Insulin Infusion Versus Intensive Insulin Therapy in Patients with Newly Diagnosed Type 1 Diabetes (IMDIAB 8). Diabetes Technology and Therapeutics, 2003, 5, 965-974.	4.4	24
88	Cytokine profile and insulin antibody IgG subclasses in patients with recent onset Type 1 diabetes treated with oral insulin. Diabetologia, 2004, 47, 1795-1802.	6.3	24
89	Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial. Science Translational Medicine, 2022, 14, .	12.4	24
90	SMART diabetes: the way to go (Safe and Multifactorial Approach to reduce the Risk for Therapy in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.3	23

#	Article	IF	Citations
91	Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2192-e2206.	3.6	23
92	Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths. Diabetes Research and Clinical Practice, 2021, 171, 108444.	2.8	23
93	Frequency of diabetes and thyroid autoantibodies in patients with autoimmune endocrine disease from Cameroon. Clinical Immunology, 2006, 118, 229-232.	3.2	21
94	Immunomodulation for the Prevention of SPIDDM and LADA. Annals of the New York Academy of Sciences, 2006, 1079, 90-98.	3.8	21
95	Bovine ?-casein antibodies in breast- and bottle-fed infants: their relevance in Type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2001, 17, 51-54.	4.0	20
96	Relation of Body Circumferences to Cardiometabolic Disease in Overweight-Obese Subjects. American Journal of Cardiology, 2016, 118, 822-827.	1.6	20
97	Proof-of-concept Raman spectroscopy study aimed to differentiate thyroid follicular patterned lesions. Scientific Reports, 2017, 7, 14970.	3.3	20
98	Effect of Calcitriol on Bone Turnover and Osteocalcin in Recent-Onset Type 1 Diabetes. PLoS ONE, 2013, 8, e56488.	2.5	20
99	Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of shortâ€acting and other glucagonâ€like peptideâ€1 receptor agonists. Diabetes/Metabolism Research and Reviews, 2016, 32, 497-511.	4.0	19
100	Conversation Mapsâ„¢, an effective tool for the management of males and females with type 2 diabetes and mildly impaired glycemic control. Hormones, 2018, 17, 113-117.	1.9	19
101	Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus. Expert Opinion on Biological Therapy, 2016, 16, 841-846.	3.1	18
102	A pilot study of d-chiro-inositol plus folic acid in overweight patients with type 1 diabetes. Acta Diabetologica, 2017, 54, 361-365.	2.5	18
103	Buccal spray insulin in subjects with impaired glucose tolerance: the prevoral study. Diabetes, Obesity and Metabolism, 2011, 13, 42-46.	4.4	17
104	The addition of E (Empowerment and Economics) to the ABCD algorithm in diabetes care. Journal of Diabetes and Its Complications, 2015, 29, 599-606.	2.3	17
105	Frailty and geography: should these two factors be added to the ABCDE contemporary guide to diabetes therapy?. Diabetes/Metabolism Research and Reviews, 2016, 32, 169-175.	4.0	17
106	SARSâ€CoVâ€2 induced postâ€translational protein modifications: A trigger for developing autoimmune diabetes?. Diabetes/Metabolism Research and Reviews, 2022, 38, e3508.	4.0	17
107	Ladarixin, an inhibitor of the interleukinâ€8 receptors <scp>CXCR1</scp> and <scp>CXCR2</scp>, in newâ€onset type 1 diabetes: A multicentre, randomized, doubleâ€blind, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2022, 24, 1840-1849.	4.4	17
108	Blue eyes as a risk factor for type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2011, 27, 609-613.	4.0	16

#	Article	IF	Citations
109	Glycemic Variability Assessed by Continuous Glucose Monitoring and Short-Term Outcome in Diabetic Patients Undergoing Percutaneous Coronary Intervention: An Observational Pilot Study. Journal of Diabetes Research, 2015, 2015, 1-11.	2.3	16
110	Antibodies to oxidized insulin improve prediction of type 1 diabetes in children with positive standard islet autoantibodies. Diabetes/Metabolism Research and Reviews, 2019, 35, e3132.	4.0	16
111	A 6-month follow-up study of the randomized controlled Ma-Pi macrobiotic dietary intervention (MADIAB trial) in type 2 diabetes. Nutrition and Diabetes, 2016, 6, e222-e222.	3.2	15
112	DiaPep277 peptide therapy in the context of other immune intervention trials in type 1 diabetes. Expert Opinion on Biological Therapy, 2011, 11, 1233-1240.	3.1	14
113	Heterogeneity of T1DM raises questions for therapy. Nature Reviews Endocrinology, 2012, 8, 78-80.	9.6	14
114	PTH(1â€“34) for the Primary Prevention of Postthyroidectomy Hypocalcemia: The THYPOS Trial. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4039-4045.	3.6	14
115	Gut microbiome response to shortâ€term dietary interventions in reactive hypoglycemia subjects. Diabetes/Metabolism Research and Reviews, 2017, 33, e2927.	4.0	14
116	Autoantibodies to postâ€translationally modified type I and II collagen in Charcot neuroarthropathy in subjects with type 2 diabetes mellitus. Diabetes/Metabolism Research and Reviews, 2017, 33, e2839.	4.0	14
117	The Mediterranean diet increases glucagonâ€like peptide 1 and oxyntomodulin compared with a vegetarian diet in patients with type 2 diabetes: A randomized controlled crossâ€over trial. Diabetes/Metabolism Research and Reviews, 2021, 37, e3406.	4.0	14
118	A practical approach to the clinical challenges in initiation of basal insulin therapy in people with type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2021, 37, e3418.	4.0	14
119	Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery. Liver International, 2022, 42, 374-383.	3.9	14
120	Type 1 Diabetes at Presentation: the Scene Changes. Diabetic Medicine, 1990, 7, 762-763.	2.3	13
121	Westernization of the Filipino population resident in Rome: obesity, diabetes and hypertension. Diabetes/Metabolism Research and Reviews, 2008, 24, 364-370.	4.0	13
122	Do we need continuous glucose monitoring in type 2 diabetes?. Diabetes/Metabolism Research and Reviews, 2013, , n/a-n/a.	4.0	13
123	Treatment of reactive hypoglycemia with the macrobiotic Ma-pi 2 diet as assessed by continuous glucose monitoring: The MAHYP randomized crossover trial. Metabolism: Clinical and Experimental, 2017, 69, 148-156.	3.4	13
124	Biomarkers of response to alpha-lipoic acidâ€‰Â±â€‰palmitoiletanolamide treatment in patients with diabetes and symptoms of peripheral neuropathy. Endocrine, 2019, 66, 178-184.	2.3	13
125	A 10â€year (1996â€“2005) prospective study of the incidence of Type 1 diabetes in Moscow in the age group 0â€“14Âyears. Diabetic Medicine, 2008, 25, 956-959.	2.3	12
126	Clinical Update on the Use of Immuno Modulators (antiCD3, GAD, Diapep277, Anti-IL1) in Type 1 Diabetes. Current Pharmaceutical Design, 2011, 17, 3224-3228.	1.9	12

#	Article	IF	Citations
127	Diet and diabetes: a cornerstone for therapy. Diabetes/Metabolism Research and Reviews, 2014, 30, 1-3.	4.0	11
128	A Novel Threeâ€Compartmental Model for Artificial Pancreas: Development and Validation. Artificial Organs, 2017, 41, E326-E336.	1.9	11
129	High Prevalence of Autoimmune Diabetes and Poor Glycaemic Control among Adults in Madagascar: A Brief Report from a Humanitarian Health Campaign in Ambanja. Journal of Diabetes Research, 2017, 2017, 1-5.	2.3	11
130	Diabetes mellitus and atrial remodelling in patients with paroxysmal atrial fibrillation: Role of electroanatomical mapping and catheter ablation. Diabetes and Vascular Disease Research, 2018, 15, 185-195.	2.0	11
131	Cardiovascular Autonomic Neuropathy as a New Complication of Postsurgical Chronic Hypoparathyroidism. Journal of Bone and Mineral Research, 2019, 34, 475-481.	2.8	11
132	The Vicious Circle of Left Ventricular Dysfunction and Diabetes: From Pathophysiology to Emerging Treatments. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3075-e3089.	3.6	11
133	An extra virgin olive oilâ€enriched chocolate spread positively modulates insulinâ€resistance markers compared with a palm oilâ€enriched one in healthy young adults: A doubleâ€blind, crossâ€over, randomised controlled trial. Diabetes/Metabolism Research and Reviews, 2022, 38, e3492.	4.0	11
134	Diabetes and cows' milk. Lancet, The, 1996, 348, 1655.	13.7	10
135	Unexpectedly high rates of obesity and dysglycemia among villagers in Cameroon. Diabetes/Metabolism Research and Reviews, 2010, 26, 10-12.	4.0	10
136	Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index. Diabetes, Obesity and Metabolism, 2019, 21, 2660-2666.	4.4	10
137	Development of a clinical risk score to predict death in patients with COVIDâ€19. Diabetes/Metabolism Research and Reviews, 2022, 38, e3526.	4.0	10
138	Inhaled insulin in type 1 diabetes. Lancet, The, 2001, 357, 1980.	13.7	9
139	The impact of type 2 diabetes on the development of tendinopathy. Diabetes/Metabolism Research and Reviews, 2021, 37, e3417.	4.0	9
140	Blood Glucose Level Forecasting on Type-1-Diabetes Subjects during Physical Activity: A Comparative Analysis of Different Learning Techniques. Bioengineering, 2021, 8, 72.	3.5	9
141	Wrist circumference: A new marker for insulin resistance in African women with polycystic ovary syndrome. World Journal of Diabetes, 2020, 11, 42-51.	3.5	9
142	Goiter in Paintings by Rogier van der Weyden (1399â€“1464). Thyroid, 2015, 25, 559-562.	4.5	8
143	Increased sclerostin and bone turnover after diet-induced weight loss in type 2 diabetes: a post hoc analysis of the MADIAB trial. Endocrine, 2017, 56, 667-674.	2.3	8
144	Hypoglycaemia and its management in primary care setting. Diabetes/Metabolism Research and Reviews, 2020, 36, e3332.	4.0	8

#	Article	IF	Citations
145	Association of bone biomarkers with advanced atherosclerotic disease in people with overweight/obesity. Endocrine, 2021, 73, 339-346.	2.3	8
146	New prospects for immunotherapy at diagnosis of type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2009, 25, 299-301.	4.0	7
147	Diagnosis of diabetes type in children and young people: challenges and recommendations. Lancet Diabetes and Endocrinology,the, 2016, 4, 385-386.	11.4	7
148	â€œThe Penitent Magdaleneâ€• Tiziano Vecellio (1488/1490â€“1576). Journal of Endocrinological Investigation, 2016, 39, 835-836.	3.3	7
149	Risk of cardiac autonomic neuropathy in latent autoimmune diabetes in adults is similar to type 1 diabetes and lower compared to type 2 diabetes: A crossâ€sectional study. Diabetic Medicine, 2021, 38, e14455.	2.3	7
150	SGLT-2 Inhibitors on Top of Current Pharmacological Treatments for Heart Failure: A Comparative Review on Outcomes and Cost Effectiveness. American Journal of Cardiovascular Drugs, 2022, 22, 263-270.	2.2	7
151	Buccal spray insulin (Oralgen) for type 2 diabetes: what evidence?. Expert Opinion on Biological Therapy, 2012, 12, 767-772.	3.1	6
152	Methylation Analysis in Distinct Immune Cell Subsets in Type 1 Diabetes. Methods in Molecular Biology, 2015, 1433, 143-151.	0.9	6
153	The effect of macrobiotic Ma-Pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the MADIAB trial. BMJ Open Diabetes Research and Care, 2015, 3, e000079.	2.8	6
154	Relation of Platelet Indexes to Platelet Reactivity and Periprocedural Myocardial Infarction in Patients Who Underwent Percutaneous Coronary Angioplasty. American Journal of Cardiology, 2018, 121, 1027-1031.	1.6	6
155	The utility of assessing C-peptide in patients with insulin-treated type 2 diabetes: a cross-sectional study. Acta Diabetologica, 2021, 58, 411-417.	2.5	6
156	Usefulness of Color Doppler Ultrasonography in the Risk Stratification of Thyroid Nodules. European Thyroid Journal, 2021, 10, 339-344.	2.4	6
157	Physical exercise, public health and quality of life in diabetes. Diabetes/Metabolism Research and Reviews, 2009, 25, S1-3.	4.0	5
158	Natural history and immunopathogenesis of type 1 diabetes. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2009, 56, 50-52.	0.8	5
159	Effect of GLPâ€1 and GIP on Câ€peptide secretion after glucagon or mixed meal tests: Significance in assessing Bâ€cell function in diabetes. Diabetes/Metabolism Research and Reviews, 2017, 33, e2899.	4.0	5
160	The use of flash glucose monitoring significantly improves glycemic control in type 2 diabetes managed with basal bolus insulin therapy compared to self-monitoring of blood glucose: A prospective observational cohort study. Diabetes Research and Clinical Practice, 2022, 183, 109172.	2.8	5
161	Immunotherapy for Type 1 diabetes: getting beyond a negative first impression. Immunotherapy, 2012, 4, 655-658.	2.0	4
162	Severe Hypophosphatemic Osteomalacia Secondary to Fanconi Syndrome Due to Adefovir: A Case Report. Endocrine Practice, 2014, 20, e246-e249.	2.1	4

#	Article	IF	Citations
163	Why China guidelines for type 2 diabetes represent an opportunity for treating this disease. Diabetes/Metabolism Research and Reviews, 2016, 32, 438-439.	4.0	4
164	Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes. Current Diabetes Reports, 2018, 18, 138.	4.2	4
165	The reconstructed natural history of type 1 diabetes mellitus. Nature Reviews Endocrinology, 2019, 15, 256-257.	9.6	4
166	Third dose of COVIDâ€19 vaccine in diabetes: Relevance of good metabolic control to improve its efficacy. Diabetes/Metabolism Research and Reviews, 2022, 38, e3533.	4.0	4
167	Immuno-intervention and preservation of beta-cell function in type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2007, 23, 255-256.	4.0	3
168	Hot topics on diabetes in China. Diabetes/Metabolism Research and Reviews, 2015, 31, 779-780.	4.0	3
169	Diabetes on demand and novel technologies. Diabetes/Metabolism Research and Reviews, 2018, 34, e2985.	4.0	3
170	â€œMadonna of the carnationâ€• Leonardo da Vinci (1452â€“1519). Journal of Endocrinological Investigation, 2018, 41, 879-880.	3.3	3
171	A novel germline mutation at exon 10 of MEN1 gene: a clinical survey and positive genotype-phenotype analysis of a MEN1 Italian family, including monozygotic twins. Hormones, 2018, 17, 427-435.	1.9	3
172	Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination. European Endocrinology, 2021, 17, 12.	1.5	3
173	Contribution of rare variants in monogenic diabetes-genes to early-onset type 2 diabetes. Diabetes and Metabolism, 2022, 48, 101353.	2.9	3
174	Unveiling a novel type 1 diabetes endotype: Opportunities for intervention. Diabetes/Metabolism Research and Reviews, 2022, 38, e3536.	4.0	3
175	Trends of glucose, lactate and ketones during anaerobic and aerobic exercise in subjects with type 1 diabetes: The ACTIONâ€1 study. Diabetes/Metabolism Research and Reviews, 2022, 38, e3537.	4.0	3
176	â€“to: Gale EAM (2002) A missing link in the hygiene hypothesis? Diabetologia 45:588â€“592. Diabetologia, 2003, 46, 301-302.	6.3	2
177	Position <scp>S</scp>tatement on the management of continuous subcutaneous insulin infusion (<scp>CSII</scp>): The Italian Lazio experience. Journal of Diabetes, 2016, 8, 41-44.	1.8	2
178	Novel blood glucose lowering therapies for managing type 1 diabetes in paediatric patients. Expert Opinion on Pharmacotherapy, 2018, 19, 355-364.	1.8	2
179	Cardiovascular autonomic neuropathy as a cause of fatigue in chronic hypoparathyroidism. Endocrine, 2020, 67, 198-203.	2.3	2
180	Our Lady of Carmel and Saints of Pietro Novelli (1603â€“1647). Journal of Endocrinological Investigation, 2020, 43, 1045-1046.	3.3	2

#	Article	IF	Citations
181	Prevention of Type 1 Diabetes Mellitus. , 2010, , 803-820.		2
182	Natural history and immunopathogenesis of type 1 diabetes. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2009, 56 Suppl 4, 50-2.	0.8	2
183	Genetic Screening and Prevention of Type 2 Diabetes. , 2005, , 81-92.		1
184	Blood glucose monitoring in the normal population: the PREDICA study. Acta Diabetologica, 2011, 48, 29-34.	2.5	1
185	â€œThe Annunciationâ€â€”Girolamo Francesco Maria Mazzola called Parmigianino (1503â€“1540). Journal of Endocrinological Investigation, 2015, 38, 1247-1248.	3.3	1
186	A Goiter in Christ in Crucifixion. Thyroid, 2016, 26, 1646-1647.	4.5	1
187	Epidemiology and Risk Factors of Type 1 Diabetes. Endocrinology, 2018, , 1-15.	0.1	1
188	Exophthalmos or pseudo-exophthalmos in the Last Judgement (1535â€“1541) by Michelangelo Buonarroti (1475â€“1564). Journal of Endocrinological Investigation, 2018, 41, 1485-1486.	3.3	1
189	A case of pheochromocytoma with negative MIBG scintigraphy, PET-CT and genetic tests (VHL included) and a rare case of post-operative erectile dysfunction. Hormones, 2018, 17, 279-284.	1.9	1
190	The Altarpiece of Saint Josephâ€™s Church in Scicli (Sicily). Journal of Endocrinological Investigation, 2020, 43, 121-122.	3.3	1
191	Comment on So et al. Autoantibody Reversion: Changing Risk Categories in Multiple-Autoantibodyâ€“Positive Individuals. Diabetes Care 2020;43:913â€“917. Diabetes Care, 2020, 43, e102-e102.	8.6	1
192	Medical congresses at the click of a mouse. Diabetes Research and Clinical Practice, 2021, 175, 108829.	2.8	1
193	Cosimo I de Medici and his Merseburg triad of Gravesâ€™ disease. Journal of Endocrinological Investigation, 2021, 44, 2853-2854.	3.3	1
194	Obesity and Glucose Metabolism. , 2015, , 107-119.		1
195	Pathogenic variants of MODY-genes in adult patients with early-onset type 2 diabetes. Acta Diabetologica, 2022, , 1.	2.5	1
196	Prevalence of serological markers for hepatitis-B in patients with insulin-dependent diabetes. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 1991, 8, 5-6.	0.2	0
197	Puppet with a voluminous goiter. Journal of Endocrinological Investigation, 2003, 26, 595-595.	3.3	0
198	Quali fattori aumentano lâ€™incidenza del diabete di tipo 1 in Italia. L Endocrinologo, 2007, 8, 80-84.	0.0	0

#	Article	IF	Citations
199	Quale terapia precoce per il diabete autoimmune dellâ€™adulto?. L Endocrinologo, 2011, 12, 2-7.	0.0	0
200	Evolution of ectopic lymphoid neogenesis and in situ autoantibodies production in autoimmune diabetic NOD mice: cellular and molecular characterisation of tertiary lymphoid structures in pancreatic islets. Annals of the Rheumatic Diseases, 2011, 70, A54-A54.	0.9	0
201	Lâ€™immunoterapia del diabete di tipo 1. L Endocrinologo, 2013, 14, 111-114.	0.0	0
202	Comment on: â€œEarly insulin treatment in type 2 diabetes: ORIGINal sin or valuable choice as ORIGINal treatment? An open debate on the ORIGIN study resultsâ€. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, e1.	2.6	0
203	Mucocutaneous Manifestations of Endocrine Disorders. , 2014, , 206-225.		0
204	Will we ever cure diabetes?. Diabetes Management, 2014, 4, 219-221.	0.5	0
205	Sleeping Cupid by Caravaggio: What Diagnosis?. Endocrine Practice, 2017, 23, 881-884.	2.1	0
206	Fast publication, a must for a journal. Diabetes/Metabolism Research and Reviews, 2018, 34, e2978.	4.0	0
207	Diabetes: the disease of the 10 D. Endocrine, 2018, 61, 353-354.	2.3	0
208	P4766Hyperleptinemia as risk factor for high platelet reactivity and cardiovascular events in patients undergoing percutaneous coronary intervention. European Heart Journal, 2018, 39, .	2.2	0
209	Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination. European Endocrinology, 2021, 1, 12.	1.5	0
210	Drug-Induced Endocrine Autoimmunity. , 2011, , 157-179.		0
211	Diabetes and Auditory Risk: the Recent Data. International Journal of Clinical Reviews, 0, , .	0.1	0
212	Prevention of Type 1 Diabetes Mellitus. , 2015, , 1-16.		0
213	Prevention of Type 1 Diabetes Mellitus. , 2017, , 1015-1030.		0
214	Reduction of HbA1c with dulaglutide in type 2 diabetes (T2D) patients negative, low positive or high positive for GAD antibodies (GADA): a post hoc analysis of AWARD -2, -4 and -5. Diabetologie Und Stoffwechsel, 2018, 13, .	0.0	0